News and research before you hear about it on CNBC and others. Claim your 1 week free trial StreetInsider Premium here.
The Testing Times report reflects expert opinion that “supporting wider deployment of rapid diagnostic technology should be a key goal of efforts to tackle the next hidden pandemic.”
LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next generation point-of-care diagnostics company, in partnership with the British In Vitro Diagnostics Association, today released the Testing Times report , which outlines the role of rapid diagnostics in combating antibiotic resistance (AMR) and identifies barriers to its introduction in primary and outpatient care.
Patients with symptoms of respiratory infections in primary care are often prescribed antibiotics without determining whether the patient has a bacterial infection that can be treated with antibiotics. This is despite the availability of published evidence of the value of rapid C-reactive protein testing, which significantly reduces antibiotic prescribing, according to a report published today.
“As we continue to evolve from the pressures and challenges that COVID-19 is putting on the NHS, it is vital that the UK Government looks to the future and the approaching AMR crisis,” said Doris-Ann Williams, CEO of British In Vitro Diagnostic Association. “Rapid diagnostics have a key role to play in the community and in primary care to reduce unnecessary antibiotic prescriptions, particularly for respiratory infections, and protect healthcare systems for decades to come.”
To inform the report, healthcare professionals, academics and government advisers on AMR shared their insights into the policy and frontline challenges in a series of interviews led by Professor Jonathan Cooke, Visiting Professor at NIHR London In Vitro Diagnostics Co- operative, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London and Honorary Professor, Faculty of Biology, Medicine and Health, University of Manchester.
Point-of-care CRP testing reduces antibiotic prescribing for respiratory tract infections (RTI) by 22-36%,1 and 22% for COPD.2 It is one of the most effective tools to address the root cause of antibiotic resistance: unnecessary antibiotic prescribing in primary care.
The Government’s 5-year Action Plan on Antimicrobial Resistance: 2019-2024 concluded that the UK is not making best use of available diagnostic technology.3 The British In Vitro Diagnostics Association and LumiraDx are calling on the NHS, Department of Health and Social Care and NICE to unlock the potential of point-of-care CRP testing to prevent antimicrobial resistance.
- The Department for Health and Social Care and NHS England should consider easing NHS pressure by offering rapid diagnostics in new respiratory assessment centers and pharmacies.
- NICE should revise its assessment of diagnostic tests to include robust economic modeling of the impact of AMR to determine the cost-effectiveness of using rapid diagnostics.
- New integrated care systems should leverage economies of scale and need to be provided with appropriate funding arrangements and incentives to deploy rapid diagnostics in primary and outpatient care.
According to Professor Cooke, “The threat of AMR requires urgent attention and action from the UK Government. We’ve heard from experts and stakeholders across sectors that challenges and barriers remain in implementing rapid point-of-care testing that can significantly reduce unnecessary antibiotic prescribing. Implementing systems that significantly reduce antibiotic use is critical for governments committed to combating the rise of antimicrobial resistance.”
Globally, there are an estimated at least 700,000 deaths per year as a result of antimicrobial-resistant infection, and this number is expected to rise to 10 million by 2050 if no action is taken.4
The test time report can be viewed here.
About LumiraDx and the LumiraDx CRP Test
Available on the LumiraDx platform, the LumiraDx CRP Test is a rapid quantitative POC test for use with direct fingerstick, venous whole blood and venous plasma that provides C-reactive protein determination in as little as 4 minutes. Test results can help support an informed decision about prescribing antibiotics at the first appointment.
LumiraDx Limited (Nasdaq: LMDX) is a next generation point-of-care diagnostics company transforming community healthcare. Its actively controlled microfluidic technology provides fast, powerful and accessible diagnostic solutions wherever the patient is, for almost any testing scenario, creating unique testing options at the point of need.
The company offers a broad range of laboratory-like tests on a single portable platform, with more than 30 assays on the market or in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes and coagulation disorders. The company also supports highly complex laboratory tests in an accessible, high-throughput format to take advantage of current molecular laboratory operations.
LumiraDx was founded in 2014 and is based in the UK. LumiraDx diagnostic testing solutions are used worldwide by governments and leading healthcare organizations in laboratories, emergency care, physician offices, pharmacies, schools and workplaces to provide screening, aid in diagnosis and also monitor well-being as a disease.
For more information on LumiraDx, visit www.lumiradx.com.
The British In Vitro Diagnostic Association (the industry body for IVD technologies) is the focal point that supports members to deliver cost-effective patient outcomes using IVD technologies and innovation to transform patient journeys.
1. Cooke J, Llor C, Hopstaken R, Dryden M, Butler C. Respiratory tract infections (RTIs) in primary care: narrative review of point-of-care testing (POCT) for C-reactive protein (CRP) and antibacterial use in patients presenting with RTI symptoms. BMJ Open Respir Res. 2020;7(1):e000624. doi:10.1136/bmjresp-2020-000624
2. Butler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing in COPD exacerbations. N Engl. J Med. 2019;381(2):111-120. doi:10.1056/NEJMoa1803185
3. Department of Health and Welfare. UK 5 year antimicrobial resistance action plan 2019-2024. January 2019. Available: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024
4. The verification of antimicrobial resistance. Tackling drug-resistant infections worldwide: final report and recommendations. May 2016. Available from https://amr-review.org